Suzanne Greenwood is a biopharmaceutical executive leader with 25+ years oncology experience, strong leadership skills and demonstrated performance excellence in general commercial management with both domestic and international markets, sales, medical, strategic planning, negotiation, training, lead generation and executive selling to biopharmaceutical industry, GPOs, physicians and senior level management. Career achievements include management of large business units as well as entrepreneurial, fast paced environments, consistently meeting or exceeding performance expectations, building and developing top performing teams, distribution channel management, identification and execution of new market opportunities and developing strong internal and external relationships in the pharmaceutical and medical industries.
posted by Suzanne Greenwood, RN, BSN on 3月 12, 2024
The oncology market is experiencing rapid growth, driven by innovations in therapies like biomarker-directed and cell-and-gene therapies. These advancements contribute to improved overall and progression-free survival in various cancer types. However, challenges arise from accelerated approvals and meeting confirmatory trials, leading to withdrawals of oncology drugs. With the increasing complexity of data, navigating regulatory intricacies, and launching products at record speeds, manufacturers face hurdles in infrastructure development, risk spending, and effectively communicating the value of therapies. In this latest article authored by Anne Marie Robertson, Suzanne Greenwood and Sneha Varma to view key considerations to bolster your oncology and hematology drug commercial strategy. Download the full POV now.